Open Label Study of OTO-104 in Subjects With Meniere's Disease
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a 1-year, multicenter, Phase 2, open-label safety study in subjects with unilateral
Meniere's disease. Subjects will receive 1 intratympanic (IT) injection of 12 mg OTO-104 at
3-month intervals for a total of 4 injections total.